Targeting tumor suppressor gene co‐mutations in EGFR ‐mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification

Documenti analoghi

• Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study
  di: Jian‐Chun Duan, et al.
  Pubblicazione: (2026)
• Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
  di: Maxime Borgeaud, et al.
  Pubblicazione: (2025)
• Treating EGFR‐mutant nonsmall cell lung cancer is no longer a one‐size‐fits‐all approach
  di: Lauren J. Antrim, et al.
  Pubblicazione: (2025)
• Osimertinib prolongs progression‐free lung cancer survival after chemotherapy
  di: Mike Fillon
  Pubblicazione: (2024)
• Radiotherapy followed by adjuvant temozolomide improves survival for patients with aggressive IDH ‐mutated anaplastic glioma
  di: Carrie Printz
  Pubblicazione: (2026)